The pool of patients eligible for Octreolin treatment is estimated to be between 10,000 and 15,000 in the US and an equal number in Europe.
(1) Melmed et al., Guidelines for Acromegaly Management, J Clin Endocrinol Metab, May 2009, 94(5):1509-1517
(2) Sandostatin, octreotide acetate, Injection, Rx Only, Prescribing Information
About Portal Hypertension (PHT)
PHT has many causes, including liver cirrhosis and portal vein thrombosis, and often leads to the development of esophageal varices that may rupture and bleed, which can be a life-threatening event. There are no approved chronic or oral treatments for PHT in the US; off-label usage of beta blockers is common.
However, the effectiveness of beta-blockers is not satisfactory for PHT and, in addition, ~30% of patients cannot take beta-blockers due to contraindications or significant side effects.
In the acute setting (during a bleeding event), patients may undergo a surgical procedure known as band ligation and receive an IV infusion of octreotide to reduce portal hypertension. In addition to having an effect on GH and IGF-1 levels in patients with acromegaly, somatostatin analogs such as octreotide are known to be potent vasocon
|SOURCE Chiasma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved